XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Phase 3 data expected in the second half of 2024
The company has raised US$4.5 million in funding for its AI operating system
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
The collaboration brings a seamless digital experience to more formulators worldwide
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Lack of technology transfer stands out as a formidable barrier
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Subscribe To Our Newsletter & Stay Updated
